Literature DB >> 24561414

Neutrophilic urticarial dermatosis (NUD) in probable adult-onset Still disease responding to anakinra.

Ingo Hartig1, Johann Oltmann Schroeder, Ulrich Mrowietz.   

Abstract

Differential diagnosis of urticarial skin lesions not representing classic urticaria remains a challenge. Long-lasting nonpruritic urticarial plaques and the histopathologic finding of a dense infiltrate with neutrophil granulocytes are indicative for a rare entity within a group of diseases termed neutrophilic dermatoses. Here, we report a case of neutrophilic urticarial dermatosis characterized by nonpruritic urticarial skin lesions, histopathologic changes resembling Sweet syndrome, and simultaneous Still syndrome. After treatment with conventional immunosuppressives including systemic corticosteroids without disease control, the patient responded to anakinra therapy within days achieving complete remission of skin lesions and systemic symptoms including fever and high C-reactive protein.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24561414     DOI: 10.1097/RHU.0000000000000078

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  3 in total

1.  Refractory urticaria and the importance of diagnosing Schnitzler's syndrome.

Authors:  Tina Nham; Carol Saleh; Derek Chu; Stephanie L Vakaljan; Jason A Ohayon; Deborah M Siegal
Journal:  BMJ Case Rep       Date:  2019-04-29

2.  Urticaria and a rare mutation: An unusual case of neutrophilic urticarial dermatosis.

Authors:  Titilola Sode; Bianca Uzoma; Travis Vandergriff; Gregory A Hosler
Journal:  JAAD Case Rep       Date:  2020-04-24

3.  Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.

Authors:  Serena Colafrancesco; Maria Manara; Alessandra Bortoluzzi; Teodora Serban; Gerolamo Bianchi; Luca Cantarini; Francesco Ciccia; Lorenzo Dagna; Marcello Govoni; Carlomaurizio Montecucco; Roberta Priori; Angelo Ravelli; Paolo Sfriso; Luigi Sinigaglia
Journal:  Arthritis Res Ther       Date:  2019-12-11       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.